Metastatic lung cancer is lung cancer that has spread beyond the lungs to distant parts of the body. It is classified as stage IV, the most advanced stage, and it means cancer cells have traveled through the bloodstream or lymphatic system to organs like the brain, bones, liver, or adrenal glands. About 51% of lung cancers are already at the distant stage when first diagnosed, and the five-year relative survival rate for this group is 10.5%, though that number has been improving steadily with newer treatments.
How Lung Cancer Spreads
Lung cancer cells don’t stay put because they undergo a biological shift that makes them mobile. Normally, the cells lining your lungs are tightly connected to each other. In metastatic cancer, those cells lose their adhesion and take on properties that let them move through tissue, enter blood vessels, and establish new tumors elsewhere. This process is driven by the cancer switching off the molecular “glue” that holds cells together while switching on traits that help them invade surrounding tissue.
Once in the bloodstream, cancer cells face threats from the immune system. Platelets, the blood cells responsible for clotting, can form a protective shield around tumor cells, helping them survive the journey and attach to new organs. The cancer also promotes the growth of new blood vessels to feed itself, a process that accelerates both at the original tumor site and wherever new tumors take root.
Where It Typically Spreads
The most common sites for lung cancer metastasis are the brain and nervous system, bones, liver, the other lung or respiratory tract, and the adrenal glands (small hormone-producing glands on top of the kidneys). The pattern depends partly on the type of lung cancer. In small cell lung cancer, the nervous system (47%) and liver (35%) are the most frequent destinations. In adenocarcinoma, the most common subtype of non-small cell lung cancer, bone metastasis occurs in about 39% of cases and spread to the other lung in about 22%.
Stage IV is further divided into two substages. In stage IVA, cancer has spread to one distant site, to the lining around the lungs or heart, or to fluid around those organs. In stage IVB, cancer has spread to multiple spots in one or more distant organs, representing the most extensive disease.
Symptoms by Location
The symptoms of metastatic lung cancer depend heavily on where it has spread, which is why two people with the same diagnosis can feel very different.
Brain: Headaches that are often severe and accompanied by nausea, confusion, memory or personality changes, seizures, or weakness in an arm or leg. These symptoms can appear suddenly and are sometimes the first sign that lung cancer has spread.
Bones: Persistent pain, particularly in the lower back if the cancer is in the spine. Bones become weaker and may fracture more easily. Calcium can leak from damaged bones into the blood, causing dehydration and confusion. If spinal bones press on the spinal cord, you may experience leg weakness, numbness, or loss of bladder and bowel control, which requires urgent medical attention.
Liver: Pain or discomfort on the right side of the abdomen, nausea, poor appetite, weight loss, a swollen belly from fluid buildup, yellowing of the skin, and itchy skin.
Adrenal glands: Often produces no symptoms at all. If both adrenal glands are affected, hormone levels can drop, leading to fatigue, weight loss, nausea, and abdominal pain.
How It’s Diagnosed
Diagnosing metastatic lung cancer involves imaging and tissue analysis. CT scans provide detailed pictures of the chest and other organs. PET/CT scans go further by highlighting areas of high metabolic activity, which helps identify cancer that has spread to lymph nodes or distant sites. Brain MRIs are commonly used because the brain is such a frequent target for lung cancer metastasis, and MRI is more sensitive there than CT.
Beyond imaging, doctors test the tumor’s genetic profile. A sample from the tumor itself, or a blood draw called a liquid biopsy, is analyzed for specific gene mutations that drive the cancer’s growth. Liquid biopsy is particularly useful when a traditional tissue biopsy is difficult or risky. One widely used panel screens for mutations across 129 genes known to play a role in cancer. The results of this testing directly shape treatment decisions.
Treatment Based on Tumor Biology
Treatment for metastatic lung cancer has shifted dramatically toward personalized medicine. The first step is determining whether the tumor has specific genetic mutations that can be targeted with drugs designed to block them.
Targeted Therapy
Certain gene changes act as “driver mutations,” essentially the engine keeping the cancer running. The most important ones to test for are EGFR, ALK, and ROS1 mutations, because drugs targeting these tend to produce the strongest responses. Patients with EGFR mutations, for example, typically receive a pill that blocks the overactive growth signal caused by that mutation. ALK-positive cancers have several treatment options that work similarly. KRAS mutations, once considered untreatable, now have targeted drugs available or in advanced development as well.
These targeted therapies are taken as daily pills rather than infusions, and many patients tolerate them better than traditional chemotherapy. They can shrink tumors significantly and keep the cancer controlled for months or even years in some cases.
Immunotherapy
For tumors without targetable driver mutations, immunotherapy is now central to treatment. These drugs work by removing the “brakes” that cancer puts on your immune system, allowing your own immune cells to recognize and attack the tumor. How much of a protein called PD-L1 the tumor produces helps guide the approach.
When PD-L1 levels are high (present on 50% or more of tumor cells), immunotherapy alone can be effective as a first treatment. When PD-L1 levels are low or absent, immunotherapy is typically combined with chemotherapy to improve response rates. This combination approach has become the standard first-line treatment for most patients with advanced lung cancer who lack targetable mutations.
Newer Options for Small Cell Lung Cancer
Small cell lung cancer, which tends to grow and spread faster than non-small cell types, has historically had fewer treatment options. In late 2025, the FDA approved a new type of therapy for patients with extensive-stage small cell lung cancer whose disease progressed after initial chemotherapy. In clinical trials, patients receiving this treatment lived a median of 13.6 months compared to 8.3 months on standard chemotherapy, a meaningful improvement for a cancer that has been notoriously difficult to treat.
The Role of Palliative Care
Palliative care focuses on managing symptoms and maintaining quality of life, and it works alongside cancer treatment rather than replacing it. Research shows that starting palliative care early and increasing its intensity in stages leads to better symptom control, improved mood, and higher overall quality of life compared to standard care alone. Patients who receive early palliative care are also less likely to undergo aggressive treatments near the end of life that offer limited benefit and can add discomfort.
This type of care addresses pain, breathing difficulty, fatigue, nausea, anxiety, and the emotional toll of living with advanced cancer. It can involve a team of specialists including pain management doctors, social workers, and counselors who coordinate with your oncology team.
What Survival Rates Actually Mean
The overall five-year relative survival rate of 10.5% for distant-stage lung cancer is a population-level statistic based on cases diagnosed between 2016 and 2022. It includes people treated with older regimens that are no longer standard. For any individual, prognosis depends on the specific type of lung cancer, its genetic profile, where it has spread, overall health, and how well the cancer responds to treatment. Patients with certain targetable mutations or strong responses to immunotherapy can live well beyond what averages suggest. The survival landscape is changing fast enough that statistics from even a few years ago may underestimate outcomes for someone starting treatment today.